CN101129633A - 一种治疗神经衰弱的药物及其制备方法 - Google Patents
一种治疗神经衰弱的药物及其制备方法 Download PDFInfo
- Publication number
- CN101129633A CN101129633A CNA2007100560910A CN200710056091A CN101129633A CN 101129633 A CN101129633 A CN 101129633A CN A2007100560910 A CNA2007100560910 A CN A2007100560910A CN 200710056091 A CN200710056091 A CN 200710056091A CN 101129633 A CN101129633 A CN 101129633A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- radix
- hours
- oral liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 83
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title claims description 40
- 208000007443 Neurasthenia Diseases 0.000 title description 5
- 206010003549 asthenia Diseases 0.000 title description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 15
- 235000008434 ginseng Nutrition 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 241000208340 Araliaceae Species 0.000 claims description 14
- 210000000582 semen Anatomy 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 238000004821 distillation Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 235000019634 flavors Nutrition 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 239000000341 volatile oil Substances 0.000 claims description 5
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000004302 potassium sorbate Substances 0.000 claims description 3
- 229940069338 potassium sorbate Drugs 0.000 claims description 3
- 235000010241 potassium sorbate Nutrition 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 3
- 206010016256 fatigue Diseases 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000292697 Polygonum aviculare Species 0.000 abstract 1
- 235000006386 Polygonum aviculare Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 208000018299 prostration Diseases 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 38
- 241001465754 Metazoa Species 0.000 description 33
- 230000000694 effects Effects 0.000 description 15
- 230000007958 sleep Effects 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 230000002496 gastric effect Effects 0.000 description 12
- 238000001802 infusion Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 12
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 10
- 206010022437 insomnia Diseases 0.000 description 10
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229960002275 pentobarbital sodium Drugs 0.000 description 9
- 206010010904 Convulsion Diseases 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 230000036461 convulsion Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 230000002567 autonomic effect Effects 0.000 description 7
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 7
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 241001279009 Strychnos toxifera Species 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 229960005453 strychnine Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000001431 Psychomotor Agitation Diseases 0.000 description 5
- 206010038743 Restlessness Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 241000721047 Danaus plexippus Species 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010003084 Areflexia Diseases 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028527 righting reflex Effects 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- AKUVRZKNLXYTJX-UHFFFAOYSA-N 3-benzylazetidine Chemical compound C=1C=CC=CC=1CC1CNC1 AKUVRZKNLXYTJX-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000590988 Danainae Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229960001657 chlorpromazine hydrochloride Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000009396 suanzaoren Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量g生药/kg | 动物数(只) | 给药30分钟 | 给药60分钟 | 给药90分钟 | 给药120分钟 |
睡宝口服液睡宝口服液睡宝口服液氯丙嗪组对照组 | 21.210.65.30.013 | 1010101010 | 101.7±15.7*103.1±25.7105.7±16.958.7±21.2***120.9±16.4 | 79.7±31.5**90.7±26.4**101.4±17.2*57.5±20.2***125.2±19.9 | 77.8±31.5**92.2±22.1**100.1±21.7*62.0±19.8***123.0±21.4 | 84.0±29.8**99.3±22.9*105.4±21.4*68.8±22.3***123.5±14.2 |
组别 | 剂量g生药/kg | 动物数(只) | 给药30分钟 | 给药60分钟 | 给药90分钟 | 给药120分钟 |
睡宝口服液睡宝口服液睡宝口服液氯丙嗪组对照组 | 21.210.65.30.013 | 1010101010 | 15.1±7.3*13.1±6.0**23.4±6.36.4±2.1***25.7±12.4 | 12.4±5.8**13.2±6.3**17.4±6.4*6.7±2.1***27.9±13.4 | 11.5±6.9**12.9±5.9**19.7±3.47.3±2.4***26.4±13.6 | 13.7±6.7*13.7±6.5*20.4±4.66.2±2.6***24.7±11.4 |
组别 | 剂量(g生药/kg) | 动物数(只) | 自主活动次数 |
睡宝口服液睡宝口服液睡宝口服液氯丙嗪组对照组 | 21.210.65.30.013蒸馏水 | 1010101010 | 405.7±191.4*420.3±173.0*501.1±171.6353.4±120.9**673.1±270.2 |
组别 | 剂量(g生药/kg) | 动物数(只) | 自主活动次数 |
睡宝口服液睡宝口服液睡宝口服液氯丙嗪组对照组 | 21.210.65.30.013蒸馏水 | 1010101010 | 182.9±86.3***143.2±63.2**136.8±71.4*157.0±87.3**70.1±21.6 |
组别 | 剂量(g生药/kg) | 入睡动物/试验动物数 | 入睡百分率(%) |
睡宝口服液睡宝口服液睡宝口服液氯丙嗪组对照组 | 21.210.65.30.013蒸馏水 | 9/108/105/109/101/10 | 9080509010 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710056091A CN101129633B (zh) | 2007-09-19 | 2007-09-19 | 一种治疗神经衰弱的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710056091A CN101129633B (zh) | 2007-09-19 | 2007-09-19 | 一种治疗神经衰弱的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101129633A true CN101129633A (zh) | 2008-02-27 |
CN101129633B CN101129633B (zh) | 2010-05-19 |
Family
ID=39127145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710056091A Active CN101129633B (zh) | 2007-09-19 | 2007-09-19 | 一种治疗神经衰弱的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101129633B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102008643A (zh) * | 2010-12-09 | 2011-04-13 | 上海市精神卫生中心 | 一种治疗神经衰弱的合剂 |
CN104147464A (zh) * | 2014-08-26 | 2014-11-19 | 威海市妇幼保健院 | 用于护理失眠患者的中药 |
CN104222862A (zh) * | 2014-10-14 | 2014-12-24 | 史春艳 | 治疗神经衰弱的药膳制剂及其制法 |
CN105796968A (zh) * | 2016-04-19 | 2016-07-27 | 湖北午时药业股份有限公司 | 一种治疗神经衰弱失眠的夜宁颗粒及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679909A (zh) * | 2005-01-26 | 2005-10-12 | 陈卫辉 | 治疗失眠症的中药组合物及其生产方法 |
-
2007
- 2007-09-19 CN CN200710056091A patent/CN101129633B/zh active Active
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102008643A (zh) * | 2010-12-09 | 2011-04-13 | 上海市精神卫生中心 | 一种治疗神经衰弱的合剂 |
CN104147464A (zh) * | 2014-08-26 | 2014-11-19 | 威海市妇幼保健院 | 用于护理失眠患者的中药 |
CN104222862A (zh) * | 2014-10-14 | 2014-12-24 | 史春艳 | 治疗神经衰弱的药膳制剂及其制法 |
CN104222862B (zh) * | 2014-10-14 | 2016-05-11 | 中南大学湘雅医院 | 治疗神经衰弱的药膳制剂及其制法 |
CN105796968A (zh) * | 2016-04-19 | 2016-07-27 | 湖北午时药业股份有限公司 | 一种治疗神经衰弱失眠的夜宁颗粒及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101129633B (zh) | 2010-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104027529A (zh) | 一种调节血脂、血压、血糖的中药组合物及其制备方法 | |
CN100374134C (zh) | 治疗抑郁症的复方药物及其制备方法 | |
CN112294924A (zh) | 一种养心安神药物组合物及其制备方法和应用 | |
CN100409883C (zh) | 一种治疗失眠、功能性消化不良和便秘的中药组合物及其制备方法 | |
CN101129633B (zh) | 一种治疗神经衰弱的药物及其制备方法 | |
CN103417846B (zh) | 一种降糖的中药组合物及其制备方法 | |
CN1471845A (zh) | 一种以灵芝、天麻为原料的保健食品及其制备方法 | |
CN101711809A (zh) | 一种治疗产后抑郁症的药物组合物及制备方法和用途 | |
CN101167846A (zh) | 一种具有降糖作用的胶囊及其制备方法 | |
CN104383420A (zh) | 制备治疗失眠多梦药物制剂的方法 | |
CN104383421A (zh) | 用于失眠多梦的药物制剂 | |
CN105456818A (zh) | 一种含有艾叶的治疗失眠的中药组合物及其制备方法 | |
CN105796968A (zh) | 一种治疗神经衰弱失眠的夜宁颗粒及其制备方法 | |
CN100360152C (zh) | 一种治疗失眠症的药物组合物及其制备方法 | |
CN103393938B (zh) | 一种降血糖的中药组合物 | |
CN103405574B (zh) | 一种治疗高血压的药物组合物 | |
CN102579816A (zh) | 一种脑灵素片及其制备方法 | |
CN102716260B (zh) | 一种快速提高精子质量与性功能的药物 | |
CN102441103B (zh) | 一种治疗失眠症的药物 | |
CN105477302A (zh) | 一种治疗失眠症的中药组合物及其制备方法 | |
CN104352973A (zh) | 一种用于产后抑郁的中成药 | |
CN1824075B (zh) | 一种治疗偏头痛的药物组合物及其制备方法 | |
CN104888124A (zh) | 盐酸米安色林的合成工艺及其检测方法 | |
CN110251568A (zh) | 一种治疗白癜风的中药复方及其制备方法 | |
CN104223062B (zh) | 一种降压降糖的地骨皮保健口服液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JILIN KANGCHUN MEDICAL CO., LTD. Free format text: FORMER OWNER: JILIN PROVINCE HUINAN TIANYU PHARMACEUTICAL CO., LTD. Effective date: 20130823 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 135100 TONGHUA, JILIN PROVINCE TO: 132300 JILIN, JILIN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130823 Address after: The rock of 132300 cities in Jilin province north of Jilin on the west side of Renmin Road Street British Economic Development Zone Patentee after: Yoshibayashi Kojun pharmaceuticals Ltd. Address before: Beishan street 135100 Huinan County in Jilin Province town of Chaoyang No. 3 Patentee before: Jilin Province Huinan Tianyu Pharmaceutical Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine for neurasthenia and its preparation Effective date of registration: 20160708 Granted publication date: 20100519 Pledgee: Jilin private economy investment Company limited by guarantee Pledgor: Yoshibayashi Kojun pharmaceuticals Ltd. Registration number: 2016220000005 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20170828 Granted publication date: 20100519 Pledgee: Jilin private economy investment Company limited by guarantee Pledgor: Yoshibayashi Kojun pharmaceuticals Ltd. Registration number: 2016220000005 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
CP03 | Change of name, title or address |
Address after: 132011 No. 777 Yinglian Street, Panshi City, Jilin Province Patentee after: Jilin Jukang Pharmaceutical Group Co.,Ltd. Address before: 132300 People's Road to the west of Yinglian Avenue, Panshi Economic Development Zone, Jilin Province Patentee before: Yoshibayashi Kojun pharmaceuticals Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190419 Address after: 132011 No. 777 Yinglian Street, Panshi City, Jilin Province Patentee after: Panshi Jukang Pharmaceutical Co.,Ltd. Address before: 132011 No. 777 Yinglian Street, Panshi City, Jilin Province Patentee before: Jilin Jukang Pharmaceutical Group Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug for treating neurasthenia and its preparation method Effective date of registration: 20220706 Granted publication date: 20100519 Pledgee: Jilin Jiutai Rural Commercial Bank Co.,Ltd. Panshi sub branch Pledgor: Panshi Jukang Pharmaceutical Co.,Ltd. Registration number: Y2022220000028 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230705 Granted publication date: 20100519 Pledgee: Jilin Jiutai Rural Commercial Bank Co.,Ltd. Panshi sub branch Pledgor: Panshi Jukang Pharmaceutical Co.,Ltd. Registration number: Y2022220000028 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug for treating Neurasthenia and its preparation method Effective date of registration: 20230714 Granted publication date: 20100519 Pledgee: Jilin Jiutai Rural Commercial Bank Co.,Ltd. Panshi sub branch Pledgor: Panshi Jukang Pharmaceutical Co.,Ltd. Registration number: Y2023220000053 |